Altimmune Positive Pemvidutide Data at AASLD in Patients with Alcohol Use Disorder

 Results from RECLAIM Phase 2 study show treatment with pemvidutide led to significant reduction in heavy drinking days and improved outcomes on other key clinical measures in patients with AUD; generally favorable tolerability profile

RECLAIM and IMPACT findings presented at AASLD further support the differentiated profile of pemvidutide, with its balanced 1:1 glucagon/GLP-1 dual receptor activity

Company scheduled to hold End-of-Phase 2 meeting with FDA in December on design of the Phase 3 registrational program for AUD

https://finviz.com/news/419343/altimmune-presents-positive-late-breaking-pemvidutide-data-at-aasld-the-liver-meeting-2026-in-patients-with-alcohol-use-disorder